H
Hitoshi Miyazawa
Researcher at Saitama Medical University
Publications - 30
Citations - 7031
Hitoshi Miyazawa is an academic researcher from Saitama Medical University. The author has contributed to research in topics: Epidermal growth factor receptor & Gefitinib. The author has an hindex of 18, co-authored 29 publications receiving 6444 citations. Previous affiliations of Hitoshi Miyazawa include Canon Inc..
Papers
More filters
Journal ArticleDOI
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo,Akira Inoue,Kunihiko Kobayashi,Shunichi Sugawara,Satoshi Oizumi,Hiroshi Isobe,Akihiko Gemma,Masao Harada,Hirohisa Yoshizawa,Ichiro Kinoshita,Yuka Fujita,Shoji Okinaga,Haruto Hirano,Kozo Yoshimori,Toshiyuki Harada,Takashi Ogura,Masahiro Ando,Hitoshi Miyazawa,Tomoaki Tanaka,Yasuo Saijo,Koichi Hagiwara,Satoshi Morita,Toshihiro Nukiwa +22 more
TL;DR: First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy.
Journal ArticleDOI
Genetic Heterogeneity of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cell Lines Revealed by a Rapid and Sensitive Detection System, the Peptide Nucleic Acid-Locked Nucleic Acid PCR Clamp
Yoshiaki Nagai,Hitoshi Miyazawa,Huqun,Tomoaki Tanaka,Kiyoshi Udagawa,Motoyasu Kato,Shunichiro Fukuyama,Akemi Yokote,Kunihiko Kobayashi,Minoru Kanazawa,Koichi Hagiwara +10 more
TL;DR: Genetic heterogeneity of EGFR suggests that the EGFR gene is unstable in established cancers and the heterogeneity may explain variable clinical responses of lung cancers to gefitinib.
Journal ArticleDOI
First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
Akira Inoue,Kunihiko Kobayashi,Kazuhiro Usui,Makoto Maemondo,Shoji Okinaga,Iwao Mikami,Masahiro Ando,Koichi Yamazaki,Yasuo Saijo,Akihiko Gemma,Hitoshi Miyazawa,Tomoaki Tanaka,Kenji Ikebuchi,Toshihiro Nukiwa,Satoshi Morita,Koichi Hagiwara +15 more
TL;DR: This is the first report indicating that EGFR mutation-positive patients with extremely poor PS benefit from first-line gefitinib, and examination of EGFR mutations as a biomarker is recommended in this patient population.
Journal ArticleDOI
Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis.
Huqun,Shinyu Izumi,Hitoshi Miyazawa,Kuniaki Ishii,Bine Uchiyama,Tadashi Ishida,Sawako Tanaka,Ryushi Tazawa,Shunichiro Fukuyama,Tomoaki Tanaka,Yoshiaki Nagai,Akemi Yokote,Hiroki Takahashi,Toshihiko Fukushima,Kunihiko Kobayashi,Hirofumi Chiba,Makoto Nagata,Susumu Sakamoto,Koichiro Nakata,Yuji Takebayashi,Yoshihiko Shimizu,Koichi Kaneko,Michio Shimizu,Minoru Kanazawa,Shosaku Abe,Yoshikazu Inoue,Seiichi Takenoshita,Kunihiko Yoshimura,Koichiro Kudo,Teruo Tachibana,Toshihiro Nukiwa,Koichi Hagiwara +31 more
TL;DR: A candidate gene is identified, SLC34A2, that encodes a type IIb sodium phosphate cotransporter and that is mutated in six of six patients investigated, and the mutations abolished the normal gene function.
Journal ArticleDOI
Frequency of and variables associated with the EGFR mutation and its subtypes
Tomoaki Tanaka,Masaru Matsuoka,Akihisa Sutani,Akihiko Gemma,Makoto Maemondo,Akira Inoue,Shoji Okinaga,Makoto Nagashima,Satoshi Oizumi,Kazutsugu Uematsu,Yoshiaki Nagai,Gaku Moriyama,Hitoshi Miyazawa,Kenji Ikebuchi,Satoshi Morita,Kunihiko Kobayashi,Koichi Hagiwara +16 more
TL;DR: The result suggests that the female predominance in the EGFR mutation rate is a reflection of a higher frequency of adenocarcinoma in females, and the gender difference in the mutation subtypes may provide a clue for the mechanism of the occurrence of the EG FR mutation.